+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Healthcare Contract Development and Manufacturing Organization (CDMO) Market 2020-2026

  • PDF Icon


  • March 2021
  • Region: Asia Pacific
  • Orion Market Research Private Limited
  • ID: 5331916
Asia-Pacific Healthcare Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Trends Analysis Report by Services (Contract Development and Contract Manufacturing) and Forecast 2020-2026.

The Asia-Pacific healthcare CDMO market is estimated to grow significantly during the forecast period. The market is mainly driven due to the growing demand for generics drugs in the region. Cost benefits owing to low labor costs and capital expenditures are the key reasons for outsourcing to the Asia-Pacific region. India has been established as a prominent player, specifically in the manufacturing of solid dosage forms for the large-scale production of generics for the global markets. Further, generic companies in India such as Cipla Ltd., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., and Cadila Healthcare Ltd. have developed into major global generics players and further contribute to the healthcare CDMO market growth.

The Asia-Pacific market for healthcare CDMO is segregated on the basis of services and region. Based on services, the market is further classified into contract development and contract manufacturing. The contract manufacturing services segment is projected to have a significant share in the Asia-Pacific healthcare CDMO market owing to the significant adoption of outsourcing services by pharmaceutical companies across the globe. The contract development services are further classified into clinical, preclinical, and laboratory services. The clinical segment is projected to have significant growth in the market owing to increasing clinical research.

Moreover, the contract manufacturing services segment is further classified into API, finished dosage formulations, and medical devices. The API contract manufacturing services segment is significantly contributing to the growth of the market during the forecast period. Based on geography, the Asia-Pacific healthcare CDMO market is further segregated into China, India, Japan, and the Rest of Asia-Pacific. China is projected to have a considerable share in the Asia-Pacific healthcare CDMO market owing to significant investment in drug discovery and development in the country.

The companies which are contributing to the growth of the Asia-Pacific healthcare CDMO market include AbbVie Inc., Almac Group Ltd., B. Braun Melsungen AG, Boehringer Ingelheim International GmbH, Lonza Group Ltd., Pfizer Inc., and others. Product launch, merger, and acquisition, collaborations with government, and technological advancements through which market players are considerably contributing to the market growth to stay competitive in the market.

Research Methodology

The market study of the Asia-Pacific healthcare CDMO market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. The research analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for pharmaceutical and medical device companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. Asia-Pacific Healthcare CDMO Market Research and Analysis by Services

The Report Covers
  • Comprehensive research methodology of the Asia-Pacific healthcare CDMO market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific healthcare CDMO market.
  • Insights about market determinants that are stimulating the Asia-Pacific healthcare CDMO market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Market Determinants
3.1. Motivators
3.2. Restraints
3.3. Opportunities

4. Market Segmentation
4.1. Asia-Pacific Healthcare CDMO Market by Services
4.1.1. Contract Development Clinical Preclinical Laboratory Services
4.1.2. Contract Manufacturing Active Pharmaceutical Ingredients (API) Finish Dosage Formulations Medical Devices

5. Regional Analysis
5.1. China
5.2. India
5.3. Japan
5.4. Rest of Asia-Pacific

6. Company Profiles
6.1. AbbVie Inc.
6.2. Almac Group Ltd.
6.3. Baxter International, Inc.
6.4. B. Braun Melsungen AG
6.5. Boehringer Ingelheim International GmbH
6.6. Catalent Inc.
6.7. Covance Inc.
6.8. Lonza Group Ltd.
6.9. Pfizer Inc.
6.10. Thermo Fisher Scientific Inc.List of Tables
1. Asia-Pacific Healthcare Cdmo Market Research and Analysis by Services, 2019-2026 ($ Million)
2. Asia-Pacific Contract Development Market Research and Analysis by Country, 2019-2026 ($ Million)
3. Asia-Pacific Contract Manufacturing Market Research and Analysis by Country, 2019-2026 ($ Million)

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • Almac Group Ltd.
  • Baxter International, Inc.
  • B. Braun Melsungen AG
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Covance Inc.
  • Lonza Group Ltd.
  • Pfizer Inc.
  • . Thermo Fisher Scientific Inc.